GlassScriptPhysician profile
Donna M Lorntz
NPI 1144589409
$2,860.57
in general payments reported to CMS, 2019-2025
24 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2023: $479 · 2024: $989 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.80 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $643.85 | 2023-2025 | Korlym |
| Novo Nordisk INC | $400.48 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medical Device Business Services, INC. | $220.62 | 2021 | |
| Lilly USA, LLC | $187.92 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $166.93 | 2021-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $166.86 | 2024-2025 | Xyosted |
| Xeris Pharmaceuticals, INC. | $143.52 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $114.37 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $102.45 | 2024-2025 | Strensiq |
| Tolmar, INC. | $94.52 | 2024-2025 | Jatenzo |
| Neurocrine Biosciences, INC. | $77.63 | 2025 | |
| Halozyme INC | $73.47 | 2023 | |
| Pfizer INC. | $71.99 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $71.11 | 2024-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.29 | 2024-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $51.11 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $47.88 | 2023 | Farxiga |
| Beta Bionics, INC. | $40.20 | 2024 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $33.68 | 2025 | Twiist |
| Abbvie INC. | $19.54 | 2023 | |
| Amneal Pharmaceuticals LLC | $18.36 | 2023 | Unithroid |
| Ibsa Pharma INC. | $17.85 | 2023 | Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2025 | |
| Lifescan, INC. | $13.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Lorntz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.